Creative Medical Technology Holdings (CELZ) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $11.7M

Market Cap: $8.5MFounded: 2007Employees: 125+HQ: Phoenix, United States

Sector Ranking#38 in Regenerative Medicine #91 in Cell & Gene Therapy

Overview

Creative Medical Technology Holdings is a US-based regenerative medicine and immunotherapy company with a mission to improve patient lives through innovative autologous cell therapies. Its core strategy leverages two disruptive platforms: the ImmCelz™ Supercharged Autologous Immunotherapy platform for modulating immune disorders and a Rapid Autologous Stem Cell platform for orthopedic and degenerative conditions. Recent achievements include an FDA Orphan Drug Designation for ImmCelz™ in Type 1 Diabetes and a Notice of Allowance for a key patent, positioning the company in sizable markets with a potentially differentiated clinical approach.

ImmunologyOrthopedicsEndocrinologyUrogynecologyUrology

Technology Platform

A portfolio of cell therapy platforms centered on autologous cell reprogramming, including the 'supercharged' ImmCelz™ immunotherapy platform for immune modulation and a rapid point-of-care autologous stem cell platform for degenerative conditions.

Funding History

3

Total raised:$11.7M

PIPE$4.2MUndisclosedFeb 15, 2021

Series A$5MUndisclosedMar 15, 2019

Seed$2.5MUndisclosedJun 15, 2017

Opportunities

The company's platforms target massive, underserved markets like Type 1 Diabetes and chronic pain.

Successful clinical validation of its 'supercharged' autologous approach could provide a potent and differentiated therapy, while its rapid autologous platform addresses the growing demand for point-of-care regenerative solutions.

Risk Factors

The company faces significant clinical trial risk, financial uncertainty as a pre-revenue OTC micro-cap, and the operational complexity of scaling autologous cell therapies.

Intense competition from both large pharma and well-funded biotechs in the cell therapy space presents an additional major challenge.

Competitive Landscape

CELZ competes in the crowded cell therapy sector, facing rivals in Type 1 Diabetes immunomodulation (e.g., Sanofi) and orthobiologics (numerous BMAC/PRP companies). Its differentiation hinges on its 'supercharging' and 'rapid' processing claims, but it must prove superiority or cost-effectiveness against both autologous and allogeneic competitors.